NEUWAVE PR XT PROBE

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.

The National Institute of Health (NIH), Clinical Center (CC), intends to solicit a quote and enter into firm-fixed price to purchase NEUWAVE PR XT PROBE, with JOHNSON & JOHNSON HEALTH CARE SYSTEMS INC.

The Interventional Radiology (IR) Clinic in the Department of Radiology and Imaging Sciences requires the procurement of NeuWave Certus 140TM 2.45 GHZ ablation system accessories. Neoplastic disease has traditionally been approached either systemically with chemotherapy or locally with surgery or radiotherapy. Minimally invasive approaches like thermal ablation have made recent advancements in the oncology field. Thermal tumor ablation has been studied in the form of microwave, laser, high intensity focused ultrasound and cryotherapy. The NeuWave system, like other equipment used for microwave ablation, uses microwave energy at 2.45GHz and creates an alternating electric field, which causes water molecule rotation and the creation of heat. This system is used to ablate soft neoplastic tissue and can be used during both minimally invasive procedures and open surgery. The procurement of the system will improve clinical care in treating soft tissue neoplasm like liver and kidney cancers in the Interventional Radiology Clinic. Microwave ablation approach has been investigated as a treatment for unresectable hepatic tumors, both as a primary treatment, palliative treatment, and as a bridge to liver transplant. In patients with small renal tumors where preserving renal function is necessary (e.g. patients with marginal renal function, a solitary kidney, bilateral tumors), and in patients with comorbidities that would render them unfit for surgery, microwave ablation has been determined to be a viable alternative therapy. It is apparent that the benefits of adding the NeuWave Certus Ablation System in IR’s anti-neoplastic arsenal are both necessary and justified, in part due to its better efficacy profile for treating tumors that reside next to blood vessels, and its ability to stick in location (“stick mode”) which allows for safer treatments than other systems without these features.

This acquisition is being conducted using policies unique to the acquisition of commercial items prescribed in FAR Part 12, in conjunction with the policies and procedures for the competition requirements of Part 6. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.

Comments to this announcement, referencing this posting number, may be submitted to the CC, Office of Purchasing and Contracts, prior to the closing date, September 09, 2022 at 12:00 PM EST specified in this announcement, electronically to the attention of Noelle DeCenzo, Contract Specialist, Noelle.decenzo@nih.gov by the due date and time marked in this notice.